The human high molecular weight-melanoma associated antigen (HMW-MAA) is a membrane-bound chondroitin sulfate proteoglycan that is variably expressed in a high percentage of melanoma cell lines and tumors. Since the mechanism(s) regulating HMW-MAA expression has(ve) not been defined, in this study, we have examined whether promoter DNA methylation regulates the level of HMW-MAA expression. In melanoma cell lines, the level of HMW-MAA mRNA and protein expression is coordinately regulated, implicating a transcriptional control mechanism. Consistent with a role for regulation by DNA methylation, we have found that a dense CpG island flanks the human HMW-MAA gene transcriptional start site. Methylation-specific PCR and sodium bisulfite DNA sequencing analyses indicate that the HMW-MAA promoter is heavily methylated in melanoma cell lines, melanoma lesions and normal lymphocytes that do not express HMW-MAA; in contrast, the HMW-MAA promoter is not methylated in melanoma cell lines and tumors that express this antigen. In addition, HMW-MAA expression is markedly induced in HMW-MAAnegative melanoma cell lines by incubation with the DNA methyltransferase inhibitor 5-aza-2 0 -deoxycytidine. In summary, our results establish DNA methylation as a key regulator of HMW-MAA expression by human melanoma cells. This information represents a useful background to optimize immunotherapeutic strategies targeting HMW-MAA.
Introduction
The human high molecular weight-melanoma associated antigen (HMW-MAA) is a membrane-bound chondroitin sulfate proteoglycan that is expressed in over 80% of human melanoma lesions and in the majority of human melanoma cell lines (Campoli et al., 2004) . Several lines of evidence suggest that HMW-MAA, like the rat ortholog NG2, plays important roles in intracellular signal cascades important for cellular adhesion, spreading and invasion (Burg et al., 1998; Chekenya et al., 1999; Fang et al., 1999; Iida et al., 1996 Iida et al., , 2001 . These include the activation of small Rho family GTPase Cdc42 and of the adaptor protein p130cas (Eisenmann et al., 1999) , as well as the association of HMW-MAA with membrane-type 3 matrix metalloproteinase on melanoma cells (Iida et al., 2001) . Furthermore, elevated HMW-MAA expression in early tumors has been proposed to facilitate tumor progression by enhancing the activation of focal adhesion kinase (FAK) and extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) (Yang et al., 2004) . The clinical relevance of these findings is indicated by the higher frequency of HMW-MAA expression in metastatic than in primary lesions in acral lentiginous melanoma (ALM), and by the association of HMW-MAA expression in primary ALM lesions with poor prognosis (Kageshita et al., 1991 (Kageshita et al., , 1993 . Furthermore, the role of HMW-MAA in the biology of melanoma cells may account for the statistically significant association between induction of HMW-MAA-specific antibodies and survival prolongation in patients with advanced melanoma immunized with HMW-MAA mimics (Mittelman et al., 1992 (Mittelman et al., , 1994 and for the inhibition of human HMW-MAA-bearing melanoma tumor growth in SCID mice administered with HMW-MAA-specific monoclonal antibody (mAb) (Hafner et al., 2005) .
To the best of our knowledge, no information is available about the mechanisms regulating the differential expression of HMW-MAA in various types of melanomas. Therefore, in the current study, we have investigated whether promoter DNA methylation, an important mechanism of gene silencing in human malignant cells (Jones and Baylin, 2002; Karpf and Jones, 2002) , underlies the lack of HMW-MAA expression in primary ALM lesions. Herein, we demonstrate that DNA methylation plays a critical role in regulating the level of HMW-MAA expression both in melanoma cell lines and in surgically removed tumors.
Results
Correlation of HMW-MAA expression by human melanoma cell lines with promoter DNA methylation status To investigate the mechanism(s) regulating HMW-MAA expression, we analysed a small panel of melanoma cell lines which express variable levels of HMW-MAA. Analysis of HMW-MAA mRNA and protein expression using reverse transcription-PCR (RT-PCR) and Western blot, respectively, showed that M14#5 and 1520 cells do not express HMW-MAA at both mRNA and protein level, SK-MEL-5 cells express HMW-MAA weakly at the mRNA level, but do not express the protein, and A375 and M21 cells express the HMW-MAA both at the mRNA and protein level (Figure 1a and b) . Flow cytometric analysis of the five melanoma cell lines stained with the HMW-MAAspecific mAb 763.74 ( Figure 1c ) showed that the cell surface expression of HMW-MAA closely parallels that of HMW-MAA at the mRNA level (Figure 1a) , and suggests that the HMW-MAA expression in human melanoma cells is regulated primarily at the transcriptional level.
Based on the data presented above, we tested whether lack of HMW-MAA expression by melanoma cell lines could be accounted for by CpG island hypermethylation, a common mechanism of transcriptional gene silencing in human cancer cells (Jones and Baylin, 2002; Karpf and Jones, 2002) . Utilizing the human genome sequence viewer (National Center for Biotechnology Information, Bethesda, MD), we identified a genomic DNA fragment containing the HMW-MAA gene (also known as CSPG4) (GenBank accession number NC_000015: region: 73682784-73721915). Examination of this fragment indicated that the 5 0 region of the HMW-MAA gene contains a classical CpG island (406 nucleotides, 72% GC content, observed/expected CpG ratio of 0.61) (Gardiner-Garden and Frommer, 1987) . The HMW-MAA 5 0 CpG island is comprised of 32 CpGs over a 406 base pair region that spans the transcriptional start site (Figure 2a) . Analysis of the HMW-MAA gene using the computer-based promoter prediction program Promoter Scan (http://bimas.dcrt. nih.gov/molbio/Proscan) indicated that the 5 0 CpG island of the HMW-MAA gene encompasses the promoter region (À190 to þ 60).
To examine whether promoter methylation regulates HMW-MAA expression, we conducted methylationspecific PCR (MSP) analysis (Herman et al., 1996) of the HMW-MAA promoter in the human melanoma cell lines M14#5, 1520 and SK-MEL-5, which do not express, or express very low levels of HMW-MAA, and in the A375 and M21 cell lines, which express high levels of HMW-MAA (Figure 2b ). Sodium bisulfitemodified DNA was used as a template for PCR using two primer sets, one specific for the methylated HMW-MAA promoter (M) and a second one specific for the unmethylated HMW-MAA promoter (U). This experiment indicated that the HMW-MAA promoter is predominantly methylated in the melanoma cell lines M14#5 and 1520, which do not express this antigen, as well as in the cell line SK-MEL-5 which expresses low level of this antigen. In contrast, the promoter is predominantly unmethylated in the cell lines A375 and M21, which express high levels of HMW-MAA (Figure 2b ). To more precisely map and accurately determine the density of methylation of the HMW-MAA CpG island promoter in these cell lines, we next conducted sodium bisulfite DNA sequencing (Frommer et al., 1992) on a 250 base pair region of the HMW-MAA 5 0 CpG island promoter that spans the transcriptional start site. This assay revealed that the HMW-MAA promoter is densely methylated in the M14#5, 1520 and SK-MEL-5 cell lines, with an overall methylation density ranging from 83 to 96% (Figure 2c ). In contrast, the HMW-MAA 5 0 CpG island is completely unmethylated in the A375 and M21 cell lines (Figure 2c ). Dose-and time-dependent activation by 5-aza-2 0 -deoxycytidine of HMW-MAA mRNA and protein expression in melanoma cell lines. 5-aza-2 0 -deoxycytidine (DAC) is a potent DNA methyltransferase inhibitor that can reactivate the expression of methylation-silenced genes following S-phase dependent incorporation into cellular DNA (Christman, (Figure 5d -f). These effects were maximal at 1 mM DAC, similar to the effect on mRNA expression (Figure 3 ). We next determined the levels of HMW-MAA protein expression during a time course after incubation with 1 mM DAC. As shown in Figure 6 , HMW-MAA protein expression, including cell surface expression, was induced maximally 4-6 days after incubation with DAC. Taken together, these results indicate that DAC coordinately upregulates HMW-MAA mRNA and protein, including cell surface expression in these cell lines, and provide further evidence that HMW-MAA expression is primarily regulated at the transcriptional level in human melanoma cells.
Association of HMW-MAA activation by DAC with promoter hypomethylation, and of HMW-MAA re-silencing with promoter remethylation The data shown above suggest that DAC treatment may activate HMW-MAA expression as a result of promoter DNA hypomethylation. To test this possibility, utilizing MSP analysis and sodium bisulfite DNA sequencing, we measured HMW-MAA promoter methylation in the M14#5, 1520 and SK-MEL-5 cell lines following DAC treatment (Figure 7a and b). Following a 5-day incubation with 1 mM DAC, MSP analysis and sodium bisulfite DNA sequencing detected a substantial increase in the level of unmethylated HMW-MAA promoter alleles in each of these three cell lines (Figure 7a and b) . Next, we examined whether extended culture of the treated cell lines in the absence of DAC allowed resilencing of HMW-MAA gene. We observed that 3 weeks after the initial incubation with DAC, HMW-MAA expression at the mRNA and at the protein level Collectively, these results demonstrate that DACmediated induction of HMW-MAA expression correlates with promoter hypomethylation, and that these melanoma cell lines actively retarget the HMW-MAA promoter for methylation and transcriptional silencing following removal of DAC from the culture media.
Association of in vivo HMW-MAA expression in human melanoma tumors and in normal lymphocytes with promoter DNA methylation status Previously, we reported that HMW-MAA is variably expressed in human melanoma lesions, and is often not detectable in primary ALM lesions (Kageshita et al., 1993) . To examine the role of HMW-MAA promoter methylation in its expression in vivo, we analysed HMW-MAA expression and promoter methylation status in eight HMW-MAA-positive and in five HMW-MAAnegative human melanoma lesions (Table 1) , as well as in a representative HMW-MAA-negative non-neoplastic tissue, peripheral blood lymphocytes (PBL). Figure 9 shows representative examples of immunohistochemical (IHC) staining with the HMW-MAA-specific mAb 763.74, in a subset of the lesions listed in Table 1 . As indicated in the figure, HMW-MAA expression is undetectable in the lesions scored as HMW-MAAnegative, but is detectable with a homogeneous and intense staining pattern in the lesions scored as HMW-MAA positive (Figure 9 ). To determine if promoter DNA methylation levels predict the level of HMW-MAA expression in these lesions, we first utilized MSP. We detected predominant HMW-MAA promoter methylation in four (80%) out of five lesions scored as negative for HMW-MAA expression by IHC (Table 1, Figure 10a ). In contrast, in each of the melanoma lesions scored as positive for HMW-MAA expression, we detected predominantly unmethylated HMW-MAA promoter alleles (Table 1, Figure 10b ). To quantitatively assess HMW-MAA promoter methylation levels in melanoma tumors, we utilized sodium bisulfite DNA sequencing (Figure 10c ). Consistent with our MSP data, bisulfite DNA sequencing analysis showed that the HMW-MAA promoter is heavily methylated in HMW-MAA-negative melanoma lesions, but it is almost completely unmethylated in HMW-MAA-positive melanoma lesions (Figure 10c) .
Finally, we examined whether promoter DNA methylation is associated with the absence of HMW-MAA expression seen in certain normal human tissues. Consistent with our expectation, HMW-MAA was not DNA methylation silences HMW-MAA expression in melanoma W Luo et al expressed, at either the mRNA or protein level, in two normal PBL samples obtained from distinct donors (Figure 11a ; data not shown). The HMW-MAA promoter was methylated in these samples (Figure 11b and c). These results indicate that, in addition to melanoma cells, promoter DNA methylation may also play an important role in regulating HMW-MAA expression in normal human somatic tissues.
Discussion
The available evidence suggests that, in addition to being a useful target for immunotherapy of melanoma, HMW-MAA plays a critical role in tumor growth and metastasis (Mittelman et al., 1992; Iida et al., 1996; Burg et al., 1998) . Despite the biological importance of HMW-MAA, to date there has been no studies of the are closely linked, suggesting that a transcriptional mechanism regulates HMW-MAA expression. Second, the presence of a classical 5 0 CpG island in the HMW-MAA promoter is consistent with a role for DNA methylation-based regulation. Third, the HMW-MAA promoter is extensively methylated in HMW-MAAnegative human melanoma cell lines, while completely unmethylated in HMW-MAA-positive human melanoma cell lines. Fourth, treatment of HMW-MAA-negative melanoma cell lines with the DNA methyltransferase inhibitor DAC induces HMW-MAA expression in a dose-and time-dependent manner, and coincides with promoter DNA hypomethylation. In addition, removal of DAC from the culture media and long-term cell growth led to resilencing of HMW-MAA expression, coincident with remethylation of the HMW-MAA promoter region. Finally, the level of methylation of the HMW-MAA promoter predicted HMW-MAA expression in vivo, both in human melanoma cells and in normal human lymphocytes. Taken together, these data define promoter DNA methylation as a key mechanism whereby HMW-MAA expression is controlled both in vitro and in vivo.
The human HMW-MAA gene is comprised of ten exons preceded by a classical 5 0 CpG island promoter. This CpG island is heavily methylated in HMW-MAA- DNA methylation silences HMW-MAA expression in melanoma W Luo et al negative human melanoma cell lines and tissues, but is completely unmethylated in HMW-MAA-positive melanoma cell lines and primary melanoma lesions, demonstrating a close link between 5 0 CpG island methylation and lack of HMW-MAA expression. DNA methylation is known to mediate transcriptional gene silencing either by directly occluding the binding of transcriptional activators or by nucleating the formation of repressive chromatin structures at gene promoters (Jones and Baylin, 2002; Karpf and Jones, 2002) . Interestingly, DNA methylation-mediated transcriptional silencing of other melanoma antigens is well known; for example, the expression of MAGE-A1, MAGE-A2 and MAGE-A3 are each regulated by DNA methylation (Weber et al., 1994; De Smet et al., 1996; Sigalotti et al., 2002; Karpf et al., 2004) . These observations suggest that DNA methylation may serve as a common mechanism for tumor antigen gene expression control in human melanoma cells. The HMW-MAA promoter was methylated in both cultured melanoma cell lines and in primary melanoma tumors, indicating that this event is not an in vitro cell culture artifact, as has been suggested to be the case for certain methylation-silenced genes (Bestor, 2003) . Despite the extensive evidence for promoter DNA hypermethylation-mediated HMW-MAA gene silencing presented in the current study, we cannot exclude that other epigenetic control mechanisms, that is, histone code alterations (Bachman et al., 2003) , also play a role in the silencing of HMW-MAA expression in vitro and in vivo.
It is worth noting that one HMW-MAA-negative ALM melanoma lesion (sample #1) displayed an unmethylated promoter region (Figure 10a ), but did not express the HMW-MAA (Figure 9 ). These data suggest that DNA hypomethylation may be necessary but not sufficient for HMW-MAA gene expression. This finding supports a model, we recently proposed to explain the overall subtle effects of DAC treatment on cellular gene expression (Karpf et al., 2004) , and suggests that specific transcriptional activators may be required for HMW-MAA expression. The presence of unmethylated HMW-MAA promoter alleles in nonexpressing melanoma lesions (Figure 10a and c) could also reflect heterogeneous methylation of the HMW-MAA promoter within the tumor. The observed methylation of the HMW-MAA promoter in nonexpressing PBL samples suggests that DNA methylation may regulate the normal pattern of expression of this gene. However, caution must be exercised in the interpretation of this result, since only two PBL samples were utilized and methylation patterns obtained are obviously heterogeneous. At any rate the results we have obtained are in DNA methylation silences HMW-MAA expression in melanoma W Luo et al agreement with recent reports that CpG island methylation may play an important role in controlling tissuespecific gene expression in normal tissues (Futscher et al., 2002; Ching et al., 2005; Song et al., 2005) .
The results of this study have implications for the development of therapeutic strategies that specifically target HMW-MAA. Based on the apparent role of HMW-MAA as a metastasis gene, one could envision direct inhibition of HMW-MAA function as a valid therapeutic end point. In this regard, it is interesting to note that RNA interference has recently been shown to induce transcriptional silencing in mammalian cells, in certain situations, by inducing the methylation of promoter DNA (Kawasaki and Taira, 2004; Morris et al., 2004) . Thus, the HMW-MAA gene might be susceptible to targeted inactivation in vivo by RNAi. On the other hand, in vivo treatment of HMW-MAAnegative melanoma lesions with DAC or other epigenetic modulators could induce HMW-MAA expression, thus increasing the efficacy of antigen-specific antibodies and T cells. In support of the latter possibility, potentiation of tumor antigen recognition following DAC treatment has been shown in other systems, and may serve as a generally applicable mechanism to increase tumor antigen recognition by the immune system (Serrano et al., 2001; Karpf and Jones, 2002; Liu et al., 2004) . However, the possible role of HMW-MAA in tumor metastasis serves as a cautionary note for the use of DNA methyltransferase inhibitors to activate anti-tumor immunity targeting HMW-MAA. In conclusion, the information gained from this study contributes to our understanding of the mechanisms regulating HMW-MAA gene expression in malignant and normal human tissues, and should facilitate the optimization of immunotherapeutic strategies targeting HMW-MAA.
Human tissues and cells Six ALM, three superficial spreading melanomas (SSM), and one lentigo malignant melanoma (LMM) primary melanoma lesions, two metastatic melanoma lesions, and one melanocytic nevus lesion were collected at the Department of Dermatology at Kumamoto University Medical School, Kumamoto, Japan. Tissues were snap-frozen in liquid nitrogen and stored at À801C. Two peripheral blood lymphocyte samples were obtained from healthy donors at Roswell Park Cancer Institute.
Monoclonal antibodies (mAb) and polyclonal antibodies
The mouse anti-HMW-MAA mAb 763.74 and the antiidiotypic (anti-id) mAb MK2-23 have been described previously (Kusama et al., 1989; Temponi et al., 1992) . Horseradish peroxidase (HRP)-conjugated goat anti-mouse Ig antibodies were purchased from Jackson Immunoresearch (West Grove, PA). Anti-a-tubulin mAb DM-1A and R-phycoerythrin (RPE)-labeled F(ab 0 ) 2 fragments of goat antimouse Ig antibodies were purchased from Accurate Chemical & Scientific Corporation (Westbury, NY) and BD Pharmingen (San Diego, CA), respectively.
5-aza-2
0 -deoxycytidine (DAC) treatment In all experiments, DAC (Sigma-Aldrich, St Louis, MO) was dissolved in phosphate-buffered saline and the resulting solution was used to treat M14#5, 1520 and SK-MEL-5 melanoma cell lines one time, at the initial time point (day 0). For dose-response experiments, DAC was utilized at 0.25, 0.5, 1.0, 2.5 or 5 mM concentrations, and cells were harvested five days after the initial treatment. In time course experiments, 1 mM DAC was utilized, and cells were harvested each day for 7 days after the initial treatment. In other experiments, melanoma cells were harvested on day 21 after the initial treatment. In all experiments, cell growth medium was changed every 3 days.
RT-PCR and quantitative real-time PCR (qRT-PCR)
Total RNA was isolated from 1 Â 10 6 cells using Trizol Reagent (Invitrogen Corporation, Carlsbad, CA), according to the manufacturer's instructions. Purified RNA was treated with DNAseI (New England Biolabs, Beverly, MA), according to the manufacturer's instructions. cDNA was synthesized using M-MLV Reverse Transcriptase (Invitrogen). HMW-MAA expression was measured using the 5 0 -TGGCCTTCACTGTCACTGTCC-3 0 in exon 5 and 4740-4717, 5 0 -CACTTGCTTCTGGGCCGTCACTCG-3 0 in exon 7) primers, designed by DNAstar (DNASTAR Inc., Madison, WI). For RT-PCR, amplifications of HMW-MAA consisted of an initial denaturation step at 951C for 5 min, followed by 35 cycles of 30 s at 951C, 1 min at 581C and 1 min at 721C on Gene Amp PCR System 9700 (Applied Biosystems, Foster City, CA). The resulting PCR products were electrophoresed on 1.5% agarose gels, stained with ethidium bromide, and imaged with AlphaImager TM 2200 Documentation & Analysis System (Imgen Technologies, Alexandria, VA). qRT-PCR was performed using the 7300 Real-Time PCR System (Applied Biosystems). Amplification conditions were the same as above, except the annealing step was performed at 601C. qPCR MasterMix Plus SG SYBR*Green I (VWR, West Chester, PA) was utilized for qRT-PCR. HMW-MAA copy number was determined using a standard curve containing serial dilutions (10 8 -10 0 copies) of the HMW-MAA DNA amplicon. All samples were analysed in triplicate. b-actin (primers: 5 0 -GACTTCGAGCAAGAGATGGCCAC-3 0 and 5 0 -CAATGC CAGGGTACATGGTGGTG-3 0 , 265bp) was amplified as a control to evaluate cDNA input. The ratio of HMW-MAA/ b-actin was used to represent the quantitative level of HMW-MAA in each cDNA sample. Amplifications without DNA templates were performed as a negative control.
Western blot analysis Cells (1 Â 10 6 ) were washed twice with PBS and incubated for 40 min on ice with 100 ml of lysis buffer (0.05 M Tris, 0.5% TritonX-100) containing protease inhibitor cocktail (SigmaAldrich). Cellular debris was removed by centrifugation and protein concentration was determined using the Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, CA). Proteins (20 mg) were separated on 8% polyacrylamide gels and electroblotted onto an Immunobilon TM -P PVDF membrane (Millipore, Bedford, MA). Membranes were blocked overnight at 41C with 5% dry milk in PBS and 0.1% Tween-20, and then incubated with HMW-MAA-specific mAb 763.74 (2 mg/ml) for 2 h at room temperature, followed by a 30-min incubation with HRP-conjugated goat anti-mouse Ig antibodies (Jackson Immunoresearch). Signals were visualized using the ECL kit (Amersham Biosciences, Piscataway, NJ). In parallel, aTubulin was detected using the anti-a-Tubulin mAb DM-1A (Accurate Chemical and Scientific). Protein expression was analysed by densitometric scanning of bands from Western blot films. The ratio of HMW-MAA/-a-Tubulin was used to represent the quantitative level of HMW-MAA in each Western blot sample.
Flow cytometry
Cells (5 Â 10 5 ) were incubated for 1 h on ice with HMW-MAAspecific mAb 763.74 (1 mg), were washed twice with 0.5% bovine serum albumin (BSA)-PBS, and incubated for an additional 30 min on ice with an optimal amount of RPElabeled F(ab 0 )2 fragments of goat anti-mouse Ig antibodies (BD Pharmingen). Cells were then washed twice, fixed in 2% paraformaldehyde, and analysed with a FACScan TM flow cytometer (BD Biosciences, San Jose, CA). Cells (10 000) were acquired for each sample. Debris, cell clusters and dead cells were gated out by light scattered assessment before singleparameter histograms were drawn. Data were analysed with CellQuest software (BD Biosciences, San Jose, CA), and HMW-MAA cell surface expression was expressed as fluorescence intensity units. Anti-id mAb MK2-23 was used as an isotypic antibody control.
Methylation-specific PCR (MSP)
Genomic DNA was isolated using the genomic DNA isolation kit (Qiagen, Valencia, CA). DNA (2 mg) was converted with sodium bisulfite according to the method of Frommer et al. (1992) , and was subjected to MSP (Herman et al., 1996) to interrogate the methylation status of the 5 0 CpG-island promoter region of the HMW-MAA gene. Primers for MSP were designed using the software program Methprimer (Li and Dahiya, 2002) , and discriminated between methylated (forward: À181 to À157, 5 0 -GGA GTT TAA GTT TGA AAT TCG AGC-3 0 , reverse: þ 6 to À17, 5 0 -ACA AAA CTT ACG AAA AAC CAA CG-3 0 ) and unmethylated (forward: À180 to À155, 5 0 -GGG AGT TTA AGT TTG AAA TTT GAG T-3 0 , reverse: þ 8 to À17, ACA AAA CTT ACA AAA AAC CAA CAA A-3 0 ) HMW-MAA promoter alleles produced by bisulfite conversion. All PCR utilized a hot-start and included an initial incubation at 951C for 4 min, followed by 35 cycles of 951C for 40 s, 561C for 40 s and 721C for 40 s, followed by one cycle of 721C for 7 min. PCR products were separated on 2% agarose gels and visualized by ethidium bromide staining and imaging as described above. Fully methylated control DNA (M-DNA) was produced by incubation with SssI methylase (New England Biolabs, Ipswich, MA), according to the manufacturer's instructions.
Sodium bisulfite DNA sequencing Genomic DNA was isolated and converted with sodium bisulfite as described above for MSP. Primer design was accomplished using the software program Methprimer (Li and Dahiya, 2002) . Bisulfite sequencing primers, (-185 to -163, 5 0 -TGGGGGAGTTTAAGTTTGAAAT-3 0 and þ 64 to þ 39, 5 0 -ATAATCAAAATCAAAACCAAAACCA-3 0 ) were used to amplify the CpG island of HMW-MAA promoter region, following sodium bisulfite conversion. The resulting DNA amplicon was 250 bp in length and contained 26 CpG sites. PCR products were cloned into the pCR TM II vector using the TA cloning kit (Invitrogen), according to the manufacturer's instructions. A total of 10 clones from each sample were sequenced at the Roswell Park Cancer Institute DNA sequencing core facility using an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems), and the methylation status for each CpG site was determined by assessing the presence of T (unmethylated) versus C (methylated) at each CpG position, using DNA Star (DNASTAR).
Immunohistochemical (IHC) staining
Frozen tissue sections were stained with HMW-MAA-specific mAb 763.74 utilizing the indirect immunoperoxidase method as described previously (Kageshita et al., 1993) .
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